# A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection

> **NCT01366638** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 79 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** TMC435
- **DRUG:** Peginterferon alfa-2b (pegIFN alfa-2b)
- **DRUG:** Ribavirin (RBV)

## Key facts

- **NCT ID:** NCT01366638
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2014-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01366638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01366638, "A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT01366638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*